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Respiratory morbidity in preterm infants predicted by
natriuretic peptide (MR-proANP) and endothelin-1
(CT-proET-1)
Roland Gerull1,2, Roland P. Neumann1, Andrew Atkinson3, Luca Bernasconi4, Sven M. Schulzke1 and Sven Wellmann1,5
BACKGROUND: Bronchopulmonary dysplasia (BPD) is a major complication in preterm infants <32 weeks. We aimed to assess
whether plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP) and C-terminal pro-endothelin-1 (CT-proET-1)
predict respiratory morbidity.
METHODS: This was a prospective, two-center, observational cohort study. MR-proANP and CT-proET-1 were measured at day 7
(±2) of life. Associations with duration of supplemental oxygen and the composite outcome of moderate or severe BPD or death
(BPD/death) were investigated.
RESULTS: Two hundred and twenty-nine infants <32 weeks were included (median gestational age [GA] 29.6 weeks [interquartile
range 29.0–30.7], median birth weight 1150 g [IQR 840–1410]). MR-proANP and CT-proET-1 were associated with the duration of
supplemental oxygen in univariable analysis (both p < 0.001) but not after adjusting for co-factors. Infants with BPD/death showed
higher plasma levels of MR-proANP (623.50 pmol/L [IQR 458.50–881.38] vs. 308.35 pmol/L [IQR 216.72–538.10]; p < 0.001) and CT-
proET-1 (255.40 pmol/L [IQR 202.60–311.15] vs. 198.30 pmol/L [IQR 154.70–297.95]; p= 0.015) compared to infants without BPD/
death. Levels of both biomarkers were significantly associated with BPD/death in univariable models but not after adjusting for co-
factors.
CONCLUSIONS: MR-proANP and CT-proET-1 are associated with the duration of supplemental oxygen and the composite outcome
BPD/death, but their prognostic value does not complement that of clinical risk factors.
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IMPACT:
● Plasma levels of MR-proANP and CT-proET-1, measured on day 7 of life (±2 days) are associated in univariable analyses with
duration of supplemental oxygen and the combined outcome of BPD or death in VLGA infants.
● Associations between both biomarkers and respiratory morbidity do not persist in multivariable models, in particular when
gestational age is included.
● MR-proANP and CT-proET-1 have limited additional value to predict respiratory morbidity in VLGA infants compared to clinical
parameters.
INTRODUCTION
Despite advances in neonatal intensive care, bronchopulmonary
dysplasia (BPD) continues to be one of the major complications of
preterm birth. Unlike other neonatal morbidities, the rate of BPD
has remained relatively stable over the past decades, most likely
due to the improved survival of extremely preterm infants.1–3 The
burden of disease is extensive, since BPD is not only associated
with increased long-term respiratory morbidity4,5 but may also
result in increased risks for cardiovascular morbidity, growth, and
neurodevelopmental impairment as well as reduced quality of
life.4,6,7 Once BPD is established, treatment options are limited and
are symptomatic rather than curative.8 Therefore, early identifica-
tion of infants at risk for BPD development is crucial in order to
prevent sequelae of the disease. The pathogenesis of BPD is
complex and includes lung injury, alveolar growth arrest,
inflammation, oxygen toxicity, and others, which makes it
challenging to find reliable predictors. Numerous prediction tools
with modest positive and negative predictive values have been
developed, indicating that parameters that are more reliable are
urgently needed.9,10
Several biomarkers have been studied as predictors for BPD
development in preterm infants, including the vasoactive peptides
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brain-type natriuretic peptide (BNP) and endothelin-1 (ET-1). BNP
measured on day of life (DOL) 3, as well as at the age of 4 weeks,
has been previously shown to be associated with subsequent
development of BPD.11,12 Atrial natriuretic peptide (ANP) belongs,
like BNP, to the family of natriuretic peptides and is released from
atrial myocytes in response to stretching of the atrial wall.13 Both
natriuretic peptides are believed to bind at the same receptor.14
Elevated levels of ANP predict death and serious cardiovascular
events in adults.15 However, its role as predictor of respiratory
morbidity in preterm infants is largely unknown.
ET-1 acts as potent vasoconstrictor and can induce vascular
remodeling as well as fibrosis,16 which are both features of BPD. In
a previous study, we showed that plasma C-terminal pro-
endothelin-1 (CT-proET-1) was associated with the duration of
supplemental oxygen and the diagnosis of BPD, when measured
at the end of the first week of life.17 However, since three different
cohorts provided data on CT-proET-1 measurements in a cross-
sectional manner, results were therefore suggestive but not
conclusive.
Based on the association between early measured CT-proET-1
and respiratory morbidity, we conducted a prospective study to
assess the role of mid-regional pro-atrial natriuretic peptide (MR-
proANP) and CT-proET-1 as predictors for respiratory morbidity in
very low gestational age (VLGA) newborns. We hypothesized that
plasma levels of MR-proANP and CT-proET-1, measured on DOL 7,
are associated with (i) the duration of supplemental oxygen and
(ii) the development of the composite outcome of BPD/death.
Furthermore, we hypothesized that (iii) these biomarkers provide




We conducted a prospective, observational, two-center cohort
study (Clinical Trials Identifier: NCT02083562) at the Department of
Neonatology, University Children’s Hospital Basel UKBB and
University Children’s Hospital Berne, Switzerland. Both are referral
centers for high-risk infants and provide tertiary-level neonatal
care. We enrolled participating infants into the study after
obtaining written informed parental consent. The Ethics Commit-
tee of Northwestern and Central Switzerland (Basel, study No. 233/
13) and the Ethics Commission of the Canton of Berne (Berne,
study No. 2481) approved the study.
Associations and outcomes
We assessed the association between plasma levels of biomar-
kers (MR-proANP and CT-proET-1) on DOL 7 (±2 days) with the
primary outcome of duration of supplemental oxygen measured
between birth and hospital discharge. We further analyzed the
association of levels of plasma biomarkers (MR-proANP and CT-
proET-1) on DOL 7 (±2 days) with the secondary composite
outcome of BPD (defined as moderate or severe BPD according
to the NHBLI workshop definition18) or death (BPD/death). At
36 weeks post-menstrual age (PMA), we performed a standar-
dized BPD assessment.19 In additional analyses, we assessed
whether biomarkers provided additional value for BPD/death
prediction compared to clinical parameters in (i) univariable
analysis, (ii) multivariable analyses including risk factors identi-
fied by univariable analyses, or (iii) multivariable analyses
including parameters of the National Institute of Child Health
and Development (NICHD) Neonatal Research Network BPD risk
estimator.20 We also analyzed these outcomes in a subset of
patients with a GA of <27 weeks.
Duration of supplemental oxygen and mechanical ventilation
were determined as hours from birth until hospital discharge. On
the day of blood sampling, we also collected data on supple-
mental oxygen and type of ventilator support.
Clinical parameters were prospectively recorded and completed
at patient discharge from patient charts. The following definitions
were applied: small for GA: birth weight <10th percentile;
antenatal corticosteroids: any corticosteroids given for lung
maturation; chorioamnionitis: clinical or histological proof of
infection; sepsis: clinical manifestation of systemic infection,
including but not limited to positive blood culture; patent ductus
arteriosus: hemodynamically relevant, as classified by the cardiol-
ogist performing the echocardiography; intraventricular hemor-
rhage (IVH) >II° as defined by Papile et al.21; total respiratory
support: combined time of mechanical ventilation, non-invasive
positive pressure ventilation, continuous positive airway pressure,
and high flow nasal cannula.
Patients
Preterm infants <32 weeks of GA (VLGA) were eligible for this
study. Exclusion criteria were the absence of parental consent and
the presence of major congenital malformations, including
relevant congenital heart defects and primary pulmonary mal-
formations. Patients were recruited consecutively between
November 2013 and November 2017. Based on researchers’
availability, all parents or legal guardians of VLGA infants meeting
the inclusion criteria were approached.
Biomarker analysis
We took samples of 500 µL blood in EDTA microtubules on DOL 7
(±2 days) in participating infants and centrifuged the sample
within 2 h, and froze the plasma at −80 °C. BRAHMS KRYPTOR
analyzed the levels of MR-proANP and CT-proET-1 in three batches
with automated immunofluorescent assays (BRAHMS Biomarkers,
Thermo Scientific, Henningsdorf, Germany). Both fully automated
assays are based on the sandwich immunoassay technique
described in detail elsewhere.22,23
Sample size calculation
Based on results from a previous study on CT-proET-1 in VLGA
newborns,17 a minimum number of 210 neonates was required to
obtain a statistically significant regression coefficient at a level of
significance of p < 0.05 with at least 90% power. This calculation
was based on a multivariable linear regression model including
duration of supplemental oxygen as the dependent variable,
which was adequately transformed to achieve normality, and CT-
proET-1 levels as the independent variable, taking also into
account confounders, such as sex, GA, and sepsis. Considering a
10% rate of analytical or pre-analytical dropouts, we aimed for
inclusion of 231 VLGA patients for this study.
Statistical analyses
Results for the continuous variables are reported as median and
interquartile ranges [IQRs], and categorical variables are expressed
as absolute frequency with corresponding percentage. We
compared groups for continuous and categorical variables by
Wilcoxon–Mann–Whitney test and Chi-square tests, respectively.
We investigated associations using univariable and multivari-
able linear models with log10 or Box–Cox transformed duration of
supplemental oxygen as dependent variable and similarly
transformed biomarker values (MR-proANP and CT-proET-1) as
independent variables, along with the following clinical para-
meters, which are known to influence respiratory morbidity in
preterm infants: GA, birth weight z-score, ethnicity, sex, type of
respiratory support, FiO2, duration of mechanical ventilation, and
sepsis. To determine the most parsimonious multivariate model,
we included those variables significant at the 5% level in
univariate analysis and then used forwards and backwards
variable selection with the Bayesian Information Criteria as
inclusion/exclusion metric. We estimated risk factors for BPD/
death estimated by fitting univariable and multivariable logistic
regression models with BPD/death defined at 36 weeks (no/yes) as
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dependent variable, and log10 or Box–Cox transformed biomarker
values (MR-proANP and CT-proET-1), along with GA, birth weight
z-score, ethnicity, FiO2, type of respiratory support, duration of
mechanical ventilation, and sepsis as independent variables. The
final model was again identified by including those covariates
significant at the 5% level from univariate analysis and subse-
quently using forwards and backwards selection.
We investigated the predictive power of the univariable models
with BPD/death as dependent variable and the biomarkers as
independent variable (and in combination) using receiver operat-
ing characteristic (ROC) curves. A standard N-fold cross-validation
technique was implemented in which the data set was boot-
strapped and then partitioned into training and test data sets by
leaving out X of the total M records. The respective logistic model
was fit to the (M− X record) data sets (i.e., training) and then the
resulting model tested using the “left-out” X data records (i.e.,
test). We calculated the ROC curves based on the predictive results
and repeated this process for different values of X to test
sensitivity to the number of folds.
Furthermore, we analyzed whether biomarkers improved the
NICHD BPD risk estimator, when added either individually or in
combination to the seven parameters (GA, birth weight, sex,
ethnicity, postnatal day, ventilator type, and FiO2) used in the risk
estimator. We compared the area under the ROC curve (AUC) from
the resulting plots with associated 95% confidence intervals (CIs)
calculated using the DeLong approach. Throughout, a p value of
<0.05 was considered statistically significant. We performed
statistical analyses in R (R: A Language and Environment for
Statistical Computing; version 3.6.1; R Core Team 2019).
RESULTS
This study included 229 preterm infants with a median [IQR] GA
and birth weight of 29.6 weeks [27.0–30.7] and 1150 g [840–1410],
respectively. Figure 1 shows a flow chart of patient recruitment;
Table 1 provides detailed patient characteristics.
Median [IQR] plasma levels of MR-proANP and CT-proET-1 on DOL
7 (±2 days) were 341.50 pmol/L [218.50–588.82] and 202.80 pmol/L
[159.25–301.30], respectively. Median [IQR] duration of supplemental
oxygen was 72.0 h [2.5, 726.0]. Plasma levels of MR-proANP and CT-
proET-1 were positively associated in univariable analysis with the
duration of supplemental oxygen (both p < 0.001; Fig. 2).
Overall, 26 (11.3%) patients met the secondary outcome criterion
of BPD/death (Table 1). These infants were of lower GA and birth
weight than patients not developing BPD/death. Univariable
analyses revealed that patients with BPD/death showed significantly
higher median [IQR] plasma levels of MR-proANP and CT-proET-1
(623.50 pmol/L [458.50–881.38] vs. 308.35 pmol/L [216.72–538.10];
p < 0.001) and 198.30 pmol/L [154.70–297.95] vs. 255.40 pmol/L
[202.60–311.15]; p= 0.015, respectively). Both biomarkers were
negatively correlated with GA (MR-proANP p < 0.001, CT-proET-1
p < 0.001).
GA showed a predictive value for development of BPD/death
with AUC 0.85 [95% CI 0.77, 0.93] (Fig. 2a), which was superior to
that of MR-proANP (AUC 0.76 [0.65, 0.86]) and CT-proET-1 (AUC
0.61 [0.51, 0.72]).
Biomarkers were not associated with BPD/death after adjusting
for risk factors identified by univariable analyses (GA, birth weight
z-score, FiO2, sepsis; Table 2). This was true for each of the two
biomarkers and the combination of both biomarkers.
Similarly, MR-proANP and CT-proET-1 did not improve BPD
prediction compared to the multivariable model of the NICHD BPD
risk estimator (GA, birth weight, sex, ethnicity, postnatal day,
ventilator type, FiO2). This was true for inclusion of either one or
both biomarkers in the multivariate models (Fig. 3b).
Subgroup analyses of patients with high risk for BPD develop-
ment (<27 weeks GA, n= 56) showed similar results, without
additional value of MR-proANP or CT-proET-1.
DISCUSSION
To our knowledge, this is the largest prospective study assessing
MR-proANP and CT-proET-1 as markers for subsequent respira-
tory morbidity in VLGA infants. Results indicate that levels of
both biomarkers, measured on DOL 7, are associated in
univariable analysis with the duration of supplemental oxygen
and diagnosis of BPD/death at 36 weeks PMA. Plasma levels of
MR-proANP showed better predictive values than those of CT-




Final study population (n = 229)
Eligible patients (n = 523)
Congenital malformation (n = 18)
Died before day of life 7 (n = 19)
Refused consent (n = 22)
Not approached (n = 257)
Biomarker analyses failed (n = 15)
Fig. 1 Flow chart of patient recruitment.
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Table 1. Patient characteristics, levels of biomarkers, and respiratory morbidity.
All (n= 229) No BPD/death (n= 203) BPD/death (n= 26) p valuea
Gestational age (weeks)
Median 29.57 29.86 25.50 <0.001
[IQR] [27.00, 30.71] [27.79, 31.00] [24.43, 26.29]
Range 23.71–31.85 23.71–31.85 23.71–30.14
Birth weight (g)
Median 1150 g 1200 g 650 g <0.001
[IQR] [840, 1410] [910, 1450] [540, 778]
Range 370–2440 g 400–2440 g 370–1490 g
Ethnicity, n (%)
White 220 (96.1) 197 (97.0) 23 (88.5) 0.002
Hispanic 4 (1.7) 4 (2.0) 0 (0.0)
Black 5 (2.2) 2 (1.0) 3 (11.5)
Blood sampling (day of life)
Median 7 7 7 0.02
[IQR] [7, 7] [7, 7] [7, 8]
Type or respiratory supportb, n (%)
Mechanical ventilation 23 (10.0) 12 (5.9) 11 (42.3) <0.001
CPAP 104 (45.4) 92 (45.3) 12 (46.2)
None 101 (44.1) 99 (48.8) 2 (7.7)
FiO2
b
Median 0.21 0.21 0.25 <0.001
[IQR] [0.21, 0.21] [0.21, 0.21] [0.22, 0.30]
SGA, n (%) 23 (10.0) 15 (7.4) 8 (30.8) 0.001
Male, n (%) 119 (52.0) 108 (53.2) 11 (42.3) 0.402
Any antenatal steroids, n (%) 178 (77.8) 159 (78.3) 19 (73.1) 0.685
Chorioamnionitis, n (%) 51 (22.3) 43 (21.2) 8 (30.8) 0.392
Preeclampsia, n (%) 33 (14.4) 28 (13.8) 5 (19.2) 0.457
Any surfactant, n (%) 123 (53.7) 101 (49.8) 23 (84.6) 0.002
Sepsis, n (%) 42 (18.3) 27 (13.3) 15 (57.7) <0.001
PDA day 7, n (%) 50 (21.8) 37 (18.2) 13 (50.0) 0.001
IVH, n (%) 26 (11.4) 23 (11.3) 3 (11.5) 1.000
Death, n (%) 3 (1.3) 0 (0.0) 3 (11.5) <0.001
MR-proANP (pmol/L)
Median 341.50 308.35 623.50 <0.001
[IQR] [218.50, 588.82] [216.72, 538.10] [458.50, 881.38]
CT-proET-1 (pmol/L)
Median 202.80 198.30 255.40 0.015
[IQR] [159.25, 301.30] [154.70, 297.95] [202.60, 311.15]
O2 supplementation (h)
Median 72.0 43.0 2103.9 <0.001
[IQR] [2.5, 726.0] [0.75, 338.9] [1536.4, 2556.0]
Mechanical ventilation (h)
Median 6.0 1.0 412.4 <0.001
[IQR] [0.0, 47.3] [0.0, 22.0] [111.4, 769.9]
CPAP (h)
Median 414.3 164.5 938.5 <0.001
[IQR] [51.0, 740.0] [50.0, 601.0] [696.5, 1337.5]
High flow nasal cannula (h)
Median 160.3 0.0 166.3 <0.001
[IQR] [0.0, 236.5] [0.0, 177.0] [0.0, 424.5]
Total respiratory support (h)
Median 547.5 341.0 1959.0 <0.001
[IQR] [71.0, 1089.0] [60.5, 941.9] [969.8, 2466.8]
Chorioamnionitis: clinical or histological signs of infection, PDA: classified by the cardiologist as hemodynamically relevant, total respiratory support:
combined duration of mechanical ventilation, non-invasive ventilation, CPAP, and high flow nasal cannula.
BPD bronchopulmonary dysplasia, IQR interquartile range, SGA small for gestational age (birth weight <10th percentile), PDA patent ductus arteriosus, IVH
intraventricular hemorrhage (>grade II), MV mechanical ventilation.
ap Values refer to comparisons of patients “No BPD/death” and “BPD/death.”
bOn the day of blood sampling.
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proET-1. However, associations of biomarker levels with supple-
mental oxygen and BPD/death did not persist in multivariable
models, in particular when GA was included. Furthermore, both
biomarkers did not improve BPD prediction when combined
with clinical risk factors or variables used in the NICHD BPD risk
estimator.
Stressed and distended atrial myocytes release ANP in response
to volume and pressure load. Since pulmonary hyperperfusion
and elevated pulmonary pressures are risk factors for respiratory
morbidity, it is biologically plausible that elevated ANP levels may
predict BPD development. Whereas ANP is unstable, and therefore
unsuited for diagnostic use, its secretion can be estimated by
measuring the mid-regional portion of the ANP precursor pro-
natriuretic peptide (MR-proANP). While previous studies evaluat-
ing natriuretic peptides primarily focused on BNP, ANP has not
been studied as a marker of respiratory morbidity in preterm
infants. However, studies in children and adults suggest that the
diagnostic utility of BNP and ANP in terms of predicting cardiac
failure is expected to be similar.24–26 To our knowledge, no other
prospective studies on the association between ANP and
respiratory morbidity in preterm infants have been published.
Previous studies assessing BNP in preterm infants showed
moderate associations with pulmonary hypertension27,28 and BPD
development.11,12,29,30 A recent systematic review of observational
studies assessed NT-proBNP as an early marker for respiratory
morbidity in preterm infants.29 Only two small studies with
considerable risk of bias were included, thus quality of evidence
was deemed to be low. For BPD prediction, sensitivity was 0.86
[95% CI 0.57, 0.98] and specificity was 0.76 [95% CI 0.61, 0.87]. One
additional prospective study assessed BPD prediction by measur-
ing NT-proBNP on DOL 28 and included 70 patients.31 Patients who
subsequently developed moderate or severe BPD showed higher
plasma levels of NT-proBNP. In light of these results, our study adds
further evidence that increased levels of natriuretic peptides
measured at the end of the first week of life are associated in
univariable analyses with subsequent development of BPD.
All three known isoforms of endothelin (ET-1, ET-2, and ET-3) are
involved in vascular function.32 ET-1 is the dominant isoform and
therefore most frequently studied. It has a long-lasting vasocon-
strictive effect and is involved in vascular remodeling, fibrosis, cell
proliferation, and apoptosis.16,33 Since pulmonary vasoconstriction
and pulmonary hypertension are associated with BPD develop-
ment, ET-1 is likely to be involved and might have a role as an
early marker of BPD development. Since ET-1 is unstable, it is
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Fig. 2 Association of biomarkers with the duration of supplemental oxygen. a Association of Log10 transformed levels of MR-proANP with
duration of supplemental oxygen. b Association of Log10 transformed levels of CT-proET-1 with duration of supplemental oxygen. Circles
represent patients without development of BPD/death; crosses show patients with BPD/death.
Table 2. Univariable and fully adjusted multivariable estimates of
association between biomarkers and clinical parameters with BPD/
death.
BPD/death (yes/no) Univariable Multivariable
OR [95% CI] p value OR [95% CI] p value
MR-proANPa (pmol/L) 3.00 [1.83, 5.25] <0.001 — nS
CT-proET-1a (pmol/L) 1.63 [1.06, 2.57] 0.03 — nS
GA (days) 0.50 [0.38, 0.62] <0.001 0.66 [0.47, 0.90] 0.01
Birth weight z-score 0.52 [0.32, 0.83] 0.007 0.49 [0.24, 0.93] 0.03
Sex
Female 1 (reference) 0.3 nS
Male 0.65 [0.28, 1.46]
Ethnicity
White 1 (reference) 0.05 nS
Non-White 4.28 [0.98, 17.43]
Type of respiratory
supportb






CPAP 6.46 [1.70, 42.21]
FiO2
b 1.29 [1.17, 1.46] <0.001 1.14 [1.02, 1.30] 0.03
Mechanical
ventilation (h)
1.01 [1.00, 1.01] <0.001 — nS
Sepsis
No 1 (reference) 1 (reference)
Yes 9.78 [4.04, 24.69] <0.001 7.76 [2.42, 28.0] <0.001
Sepsis: clinical manifestation of systemic infection, including but not
limited to positive blood culture.
GA gestational age, nS non-significant, OR odds ratio.
aBox–Cox transformation to achieve approximate normality.
bOn the day of blood sampling.
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Clinical studies have shown that ET-1 concentrations were
significantly higher in infants with respiratory distress syndrome
(RDS) than controls. Among infants with RDS, ET-1 was
significantly higher in those who later developed BPD.34
Furthermore, ET-1 was significantly elevated in tracheal aspirates
of preterm infants on DOL 1, 3, and 7 who subsequently
developed BPD.35 Only few studies evaluated CT-proET-1 for
BPD development. A previous study from our group included 227
VLGA infants and we measured plasma CT-proET-1 at birth, DOL 2,
3, 6, and 28.17 This study had a retrospective design; included
patients did not participate in the presented prospective study,
thus there was no overlap of study participants. The retrospective
study showed that predictive value of CT-proET-1 for BPD
development was poor at birth but was excellent on DOL 6.
Furthermore, CT-proET-1 levels at DOL 2, 3, 6, and 28 were
strongly related to the duration of oxygen supplementation. The
differences of BPD prediction between the previous study and the
presented prospective trial are probably related to differences in
study design and study population. The measurements in the
study by Baumann et al. were obtained from three different
cohorts, which make a bias in patient selection more likely.
Furthermore, the BPD rate was 36.6%, which is much higher than
in our prospective study (11.3%).
A prospective, observational study including preterm infants of
28–34 weeks GA assessed CT-proET-1 on DOL 3 and resulted in
BPD prediction with a sensitivity of 88.2% and specificity of 61.5%,
when a cut-off value for CT-proET-1 of 302.7 ng/L was used.36 In
light of lower chronological age at blood sampling, inclusion of
newborns with higher GA, and a remarkably high BPD rate of
24.6% in the cited study compared to 11.4% in our study, these
results seem to be not directly comparable. However, they support
the hypothesis that CT-proET-1 can serve as biomarker for early
BPD prediction.
Several attempts at establishing clinical prediction tools for BPD
development have been made in recent years, but models
typically have limited positive and negative predictive values,9
making biomarkers promising parameters to improve the
diagnostic utility of such models in order to potentially improve
clinical care. Results from our study confirm that MR-proANP and
CT-proET-1 are associated with the duration of supplemental
oxygen and development of BPD or death in very preterm infants.
However, this relationship did not persist in multivariable analyses.
Therefore, at this stage, analysis of MR-proANP and CT-proET-1
appear to have limited clinical value as sole predictors of
respiratory morbidity but could be useful as surrogate markers
of physiological immaturity and/or prematurity-related lung
disease.
Strengths of our study include the prospective design, the high
number of included infants in line with the power calculation, and
the structured BPD assessment at 36 weeks GA in all patients.
Limitations include the low rate of infants with moderate or severe
BPD in our study, and the Swiss population in general,37 which
makes generalization of results challenging.
In summary, our study showed that MR-proANP and CT-proET-1,
measured at the age of 1 week, are associated in univariable
analyses with the duration of supplemental oxygen and the
combined outcome of BPD or death in VLGA infants. However,
their additional value for BPD prediction compared to models
based solely on clinical risk factors seems to be limited.
ACKNOWLEDGEMENTS
This work was supported by a research grant from Fondazione Ettore e Valeria Rossi
to R.G. The funder had no role in study design, data collection and analysis,
preparation of the manuscript, or decision to publish.
AUTHOR CONTRIBUTIONS
R.G. was responsible for most aspects of this study at the center Berne, including
ethical approval, patient recruitment, blood sampling, and storage of samples. He
was involved in statistical analyses, interpretation of results, and wrote the initial draft
of the manuscript. R.P.N. was responsible for the study center Basel as primary
investigator, including ethical approval, patient recruitment, blood sampling, and
storage of samples. He was involved in study design and statistical analyses. A.A. was
























0.00 0.25 0.50 0.75 1.00 0.00 0.25 0.50 0.75 1.00
Fig. 3 ROC curves for the fitted logistic regression models with BPD/death as dependent variable. a Independent variables are gestational
age (solid, AUC 0.85 (95% CI [0.77, 0.93])), MR-proANP (dotted, AUC 0.76 [0.65, 0.86]), CT-proET-1 (dot-dashed, AUC 0.61 [0.51, 0.72]), and a
composite variable of MR-proANP and CT-proET-1 (dashed, AUC 0.72 [0.61, 0.83]). b Independent variables are those included in the NICHD
BPD risk estimator (solid, AUC 0.86 [0.76, 0.95]), composite variable of NICHD BPD risk estimator variables plus MR-proANP (dotted 0.84 [0.72,
0.95]), composite variable of NICHD BPD risk estimator variables plus CT-proET-1 (dot-dashed, AUC 0.82 [0.69, 0.95]), and composite variable of
NICHD plus MR-proANP plus CT-proET-1 (dashed, AUC 0.83 [0.71, 0.95]). AUC area under the curve.
Respiratory morbidity in preterm infants predicted by natriuretic peptide. . .
R Gerull et al.
6
Pediatric Research _#####################_
for processing and storage of blood samples as well as measurements of both
biomarkers. S.M.S. supervised study design and procedures of the study. He was also
involved in patient recruitment and interpretation of results. S.W. had the initial idea
of the study and was involved in various aspect of the study, including design,
optimizing procedures, patient recruitment, and sample processing. All authors
drafted the work and revised it critically for important intellectual content, agreed to
be accountable for all aspects of the work, and approved the final version of the
manuscript.
FUNDING
Open Access funding provided by Universität Basel (Universitätsbibliothek Basel).
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41390-021-01493-8.
Competing interests: The authors declare no competing interests.
Consent statement: Consent from parents or legal guardian was required and
obtained for every individual participating in this study.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Stoll, B. J. et al. Neonatal outcomes of extremely preterm infants from the NICHD
Neonatal Research Network. Pediatrics 126, 443–456 (2010).
2. Stoll, B. J. et al. Trends in care practices, morbidity, and mortality of extremely
preterm neonates, 1993-2012. JAMA 314, 1039–1051 (2015).
3. Horbar, J. D. et al. Variation in performance of neonatal intensive care units in the
United States. JAMA Pediatr. 171, e164396 (2017).
4. Bhandari, A. & Bhandari, V. Pitfalls, problems, and progress in bronchopulmonary
dysplasia. Pediatrics 123, 1562–1573 (2009).
5. Doyle, L. W. & Victorian Infant Collaborative Study Group. Respiratory function at
age 8-9 years in extremely low birthweight/very preterm children born in Victoria
in 1991-1992. Pediatr. Pulmonol. 41, 570–576 (2006).
6. Anderson, P. J. & Doyle, L. W. Neurodevelopmental outcome of broncho-
pulmonary dysplasia. Semin Perinatol. 30, 227–232 (2006).
7. van Katwyk, S. et al. Lifetime patient outcomes and healthcare utilization for
Bronchopulmonary dysplasia (BPD) and extreme preterm infants: a micro-
simulation study. BMC Pediatr. 20, 136 (2020).
8. Kair, L. R., Leonard, D. T. & Anderson, J. M. Bronchopulmonary dysplasia. Pediatr.
Rev. 33, 255–263 (2012). quiz 263–264.
9. Onland, W. et al. Clinical prediction models for bronchopulmonary dysplasia: a
systematic review and external validation study. BMC Pediatr. 13, 207 (2013).
10. Lal, C. V. & Ambalavanan, N. Biomarkers, early diagnosis, and clinical predictors of
bronchopulmonary dysplasia. Clin. Perinatol. 42, 739–754 (2015).
11. Sellmer, A. et al. N-terminal pro-B type natriuretic peptide as a marker of
bronchopulmonary dysplasia or death in very preterm neonates: a cohort study.
PLoS ONE 10, e0140079 (2015).
12. Joseph, L. et al. N-terminal pro-B-type natriuretic peptide as a marker of broncho-
pulmonary dysplasia in premature infants. Am. J. Perinatol. 27, 381–386 (2010).
13. Song, W., Wang, H. & Wu, Q. Atrial natriuretic peptide in cardiovascular biology
and disease (NPPA). Gene 569, 1–6 (2015).
14. Koller, K. J. & Goeddel, D. V. Molecular biology of the natriuretic peptides and
their receptors. Circulation 86, 1081–1088 (1992).
15. Wang, T. J. et al. Plasma natriuretic peptide levels and the risk of cardiovascular
events and death. N. Engl. J. Med. 350, 655–663 (2004).
16. Khimji, A. K. & Rockey, D. C. Endothelin–biology and disease. Cell Signal. 22,
1615–1625 (2010).
17. Baumann, P. et al. Plasma proendothelin-1 as an early marker of broncho-
pulmonary dysplasia. Neonatology 108, 293–296 (2015).
18. Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care
Med. 163, 1723–1729 (2001).
19. Walsh, M. C. et al. Impact of a physiologic definition on bronchopulmonary
dysplasia rates. Pediatrics 114, 1305–1311 (2004).
20. Laughon, M. M. et al. Prediction of bronchopulmonary dysplasia by postnatal age
in extremely premature infants. Am. J. Respir. Crit. Care Med. 183, 1715–1722
(2011).
21. Papile, L. A. et al. Incidence and evolution of subependymal and intraventricular
hemorrhage: a study of infants with birth weights less than 1,500 gm. J. Pediatr.
92, 529–534 (1978).
22. Papassotiriou, J. et al. Immunoluminometric assay for measurement of the C-
terminal endothelin-1 precursor fragment in human plasma. Clin. Chem. 52,
1144–1151 (2006).
23. Morgenthaler, N. G. et al. Immunoluminometric assay for the midregion of pro-
atrial natriuretic peptide in human plasma. Clin. Chem. 50, 234–236 (2004).
24. Chenevier-Gobeaux, C. et al. Midregional pro-atrial natriuretic peptide for the
diagnosis of cardiac-related dyspnea according to renal function in the emer-
gency department: a comparison with B-type natriuretic peptide (BNP) and N-
terminal proBNP. Clin. Chem. 56, 1708–1717 (2010).
25. Gegenhuber, A. et al. Midregional pro-A-type natriuretic peptide measurements
for diagnosis of acute destabilized heart failure in short-of-breath patients:
comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP.
Clin. Chem. 52, 827–831 (2006).
26. van Hateren, K. J. et al. Comparison of midregional pro-A-type natriuretic peptide
and the N-terminal pro-B-type natriuretic peptide for predicting mortality and
cardiovascular events. Clin. Chem. 58, 293–297 (2012).
27. Konig, K. et al. Association of BNP, NTproBNP, and early postnatal
pulmonary hypertension in very preterm infants. Pediatr. Pulmonol. 51, 820–824
(2016).
28. Avitabile, C. M. et al. Accuracy of brain natriuretic peptide for diagnosing pul-
monary hypertension in severe bronchopulmonary dysplasia. Neonatology 116,
147–153 (2019).
29. Xiong, T. et al. Natriuretic peptides in bronchopulmonary dysplasia: a systematic
review. J. Perinatol. 40, 607–615 (2020).
30. Dasgupta, S. et al. NTproBNP as a surrogate biomarker for early screening of
pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J.
Perinatol. 38, 1252–1257 (2018).
31. Khan, S. et al. Role of NT-proBNP in the prediction of moderate to severe
bronchopulmonary dysplasia in preterm infants. Pediatr. Pulmonol. 55, 376–382
(2020).
32. Barton, M. & Yanagisawa, M. Endothelin: 20 years from discovery to therapy. Can.
J. Physiol. Pharmacol. 86, 485–498 (2008).
33. Kambas, K. et al. Endothelin-1 signaling promotes fibrosis in vitro in a bronch-
opulmonary dysplasia model by activating the extrinsic coagulation cascade. J.
Immunol. 186, 6568–6575 (2011).
34. El Sayed, M. et al. Endothelin-1 and L-arginine in preterm infants with respiratory
distress. Am. J. Perinatol. 28, 129–136 (2011).
35. Niu, J. O. et al. Early increase in endothelin-1 in tracheal aspirates of preterm
infants: correlation with bronchopulmonary dysplasia. J. Pediatr. 132, 965–970
(1998).
36. El Shemi, M. S. et al. Endothelin 1 as a predictor marker for bronchopulmonary
dysplasia in preterm neonates with respiratory distress syndrome. J. Neonatal
Perinat. Med. 10, 79–83 (2017).
37. Shah, P. S. et al. Neonatal outcomes of very low birth weight and very preterm
neonates: an international comparison. J. Pediatr. 177, 144–152 e6 (2016).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
Respiratory morbidity in preterm infants predicted by natriuretic peptide. . .
R Gerull et al.
7
Pediatric Research _#####################_
